Common adverse reactions in adults
Current Mounjaro trials report dose-group-specific rates
The Eli Lilly Mounjaro prescribing information effective April 22, 2026 includes a pooled table from two placebo-controlled trials in adults with type 2 diabetes. Nausea occurred in 4% with placebo and 12%, 15%, and 18% with Mounjaro 5 mg, 10 mg, and 15 mg. The corresponding placebo, 5 mg, 10 mg, and 15 mg rates were 9%, 12%, 13%, and 17% for diarrhea; 1%, 5%, 10%, and 11% for decreased appetite; 2%, 5%, 5%, and 9% for vomiting; 1%, 6%, 6%, and 7% for constipation; 3%, 8%, 8%, and 5% for indigestion; and 4%, 6%, 5%, and 5% for abdominal pain.
- Keep every percentage tied to the branded Mounjaro adult type 2 diabetes trials, the exact dose group, and the current manufacturer label.
- Do not turn trial-group percentages into an individual forecast, combine dose groups into an invented pooled rate, or compare them with another product as though the trials were head-to-head.
- Stronger symptoms do not prove greater absorption or effectiveness, and absence of symptoms does not prove that treatment is ineffective.
Digestive effects, hydration, and glucose
A common stomach symptom can still become urgent
In the adult placebo-controlled pool, gastrointestinal reactions were reported in 20.4% with placebo and 37.1%, 39.6%, and 43.6% with Mounjaro 5 mg, 10 mg, and 15 mg. The label says most nausea, vomiting, and diarrhea reports occurred during dosage escalation and decreased over time, but it does not provide one duration for every patient. It also warns about severe gastrointestinal reactions, kidney injury from volume depletion, and increased low-blood-sugar risk when Mounjaro is used with insulin or an insulin secretagogue such as a sulfonylurea.
- Record vomiting or diarrhea episodes, bowel pattern, ability to keep fluids and food down, urine amount and color, dizziness, fainting, weakness, recent illness, and heat exposure.
- If glucose monitoring is part of care, record readings with symptoms, meals, activity, insulin, sulfonylureas, and other glucose-lowering medicines; follow the individualized response plan.
- Do not improvise a treatment hold, catch-up injection, restart, anti-nausea medicine, laxative, hydration recipe, or glucose plan from generic online advice.
Adult and pediatric label context
The current label includes ages 10 and older, while Peptide12 provides adult care
Mounjaro is indicated with diet and exercise to improve glycemic control in adults and pediatric patients age 10 and older with type 2 diabetes. The current label says adverse reactions in 97 treated pediatric patients were generally consistent with adult findings, except for higher incidences of vomiting, abdominal pain, and hypoglycemia. In the 30-week placebo-controlled period, vomiting occurred in 3%, 16%, and 12% with placebo, Mounjaro 5 mg, and 10 mg; abdominal pain occurred in 9%, 22%, and 15%. These small, population-specific groups should not be blended with adult rates.
- Peptide12 provides adult telehealth care; that service boundary is separate from the manufacturer label, which includes pediatric patients age 10 and older with type 2 diabetes.
- Adult and pediatric dosage limits, diabetes regimens, trial populations, and adverse-reaction evidence differ; never present an adult table as universal.
- A child or adolescent with symptoms needs coordination through the responsible pediatric diabetes team rather than an adult telehealth pathway.
Serious label warnings
Common digestive effects should not obscure abdominal, allergy, eye, thyroid, or procedure warning signs
The current label includes a boxed warning about thyroid C-cell tumors observed in rats; it is unknown whether Mounjaro causes these tumors in humans. Mounjaro is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Label warnings also address pancreatitis, gallbladder disease, serious hypersensitivity, diabetic-retinopathy complications in people with a history of diabetic retinopathy, and pulmonary aspiration during general anesthesia or deep sedation. A support page cannot diagnose these conditions or replace an examination.
- Seek prompt care for severe or persistent abdominal pain, especially pain that may spread to the back, with or without vomiting; jaundice, fever, or right-upper-abdominal pain also needs assessment.
- Trouble breathing or swallowing, facial or throat swelling, fainting, widespread hives, sudden vision change, a neck mass, persistent hoarseness, or rapidly developing serious symptoms requires urgent or emergency evaluation.
- Tell the procedure and anesthesia team about the exact product, presentation, symptoms, and treatment timing; do not create a self-directed hold or restart schedule.
Product and presentation identity
Mounjaro rates do not automatically apply to Zepbound or compounded tirzepatide
Mounjaro is FDA-approved tirzepatide for type 2 diabetes and is supplied in pre-filled single-dose pens, single-dose vials, multi-dose vials, and single-patient-use KwikPens with presentation-specific instructions. Zepbound also contains tirzepatide but has different indications, study populations, presentations, and adverse-reaction tables. A patient-specific compounded tirzepatide preparation is not FDA-approved Mounjaro or Zepbound and is not an FDA-approved generic finished drug product; it may differ in concentration, inactive ingredients, container, supplies, instructions, storage, and beyond-use date.
- Preserve the product name, indication, presentation, prescription and pharmacy label, manufacturer or dispensing pharmacy, refill or lot details, storage history, and a photo of the current package.
- Do not transfer Mounjaro trial rates, pen or vial instructions, storage rules, or package assumptions to Zepbound, a compounded vial, a research-use product, or an unlabeled injection.
- Avoid counterfeit or no-prescription sellers, copied syringe charts, unverified additive combinations, and claims that a compounded product is FDA-approved Mounjaro or generic Mounjaro.